Last reviewed · How we verify

Drug-Eluting Embolic Bead

Tehran University of Medical Sciences · Phase 3 active Small molecule

Drug-Eluting Embolic Bead is a Drug-eluting embolic bead Small molecule drug developed by Tehran University of Medical Sciences. It is currently in Phase 3 development for Hepatocellular carcinoma (transarterial chemoembolization), Hypervascular tumors amenable to arterial delivery. Also known as: Irinotecan-loaded drug-eluting beads (DEBIRI) plus systemic chemotherapy +/- targeted therapy.

Drug-eluting embolic beads deliver chemotherapy directly to tumors while occluding blood vessels to starve them of oxygen and nutrients.

Drug-eluting embolic beads deliver chemotherapy directly to tumors while occluding blood vessels to starve them of oxygen and nutrients. Used for Hepatocellular carcinoma (transarterial chemoembolization), Hypervascular tumors amenable to arterial delivery.

At a glance

Generic nameDrug-Eluting Embolic Bead
Also known asIrinotecan-loaded drug-eluting beads (DEBIRI) plus systemic chemotherapy +/- targeted therapy
SponsorTehran University of Medical Sciences
Drug classDrug-eluting embolic bead
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

These beads are injected into the arterial blood supply feeding a tumor, where they lodge in small vessels and release chemotherapy drugs locally over time while simultaneously causing embolization (vessel blockage). This dual mechanism—local drug delivery combined with ischemia—maximizes tumor exposure to cytotoxic agents while minimizing systemic toxicity. The approach is particularly suited for hepatocellular carcinoma and other hypervascular tumors.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Drug-Eluting Embolic Bead

What is Drug-Eluting Embolic Bead?

Drug-Eluting Embolic Bead is a Drug-eluting embolic bead drug developed by Tehran University of Medical Sciences, indicated for Hepatocellular carcinoma (transarterial chemoembolization), Hypervascular tumors amenable to arterial delivery.

How does Drug-Eluting Embolic Bead work?

Drug-eluting embolic beads deliver chemotherapy directly to tumors while occluding blood vessels to starve them of oxygen and nutrients.

What is Drug-Eluting Embolic Bead used for?

Drug-Eluting Embolic Bead is indicated for Hepatocellular carcinoma (transarterial chemoembolization), Hypervascular tumors amenable to arterial delivery.

Who makes Drug-Eluting Embolic Bead?

Drug-Eluting Embolic Bead is developed by Tehran University of Medical Sciences (see full Tehran University of Medical Sciences pipeline at /company/tehran-university-of-medical-sciences).

Is Drug-Eluting Embolic Bead also known as anything else?

Drug-Eluting Embolic Bead is also known as Irinotecan-loaded drug-eluting beads (DEBIRI) plus systemic chemotherapy +/- targeted therapy.

What drug class is Drug-Eluting Embolic Bead in?

Drug-Eluting Embolic Bead belongs to the Drug-eluting embolic bead class. See all Drug-eluting embolic bead drugs at /class/drug-eluting-embolic-bead.

What development phase is Drug-Eluting Embolic Bead in?

Drug-Eluting Embolic Bead is in Phase 3.

What are the side effects of Drug-Eluting Embolic Bead?

Common side effects of Drug-Eluting Embolic Bead include Post-embolization syndrome (fever, pain, nausea), Hepatic dysfunction, Vascular complications, Systemic chemotherapy toxicity.

Related